Here's why the biggest biotech IPO of 2019 outshines all its peers.
News & Analysis: BridgeBio Pharma Inc
Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.
This company's about to begin delivering a stream of new drugs that target genetic diseases, and hardly anyone's heard about it.
These underappreciated biotechnology start-ups could turn heads one day -- but not yet.
BridgeBio announced this week that it had terminated its effort to acquire the remaining stake in subsidiary Eidos Therapeutics. What does this mean for Eidos shareholders?
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
These small-cap biotechs have fallen to bargain prices.
These innovative healthcare companies promise investors a way to benefit from medical breakthroughs without the usual risk.
This pair of healthcare businesses made their public debut in June, but they're already making a big impression.